Additional 2023 Catalysts and Operational Objectives: Complete enrollment of the Phase 1b study of AGEN2373 and botensilimab in melanoma. Initiate combination cohorts of AGEN1571 with botensilimab and balstilimab. Potential income from existing and future collaborators. Advance 7 existing clinical collaborations evaluating combinations of external agents with our PD-1 and CTLA-4 antibodies sponsored and executed by partners.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AGEN:
- Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives
- Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement
- Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB
- Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer
- Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report
